{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-001035","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.526425+00:00","generated_at":"2026-06-14T02:48:02.575545+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexaria Bioscience dismisses CFO Gregory Downey; CEO assumes principal financial officer role","bullets":["Gregory Downey dismissed as CFO effective June 6, 2023; company actively seeking replacement.","Interim CFO services provided by Mike Shankman of NOW CFO; Shankman is CPA with MBA, healthcare experience.","CEO Chris Bunka assumes role of principal financial officer; no additional compensation for Bunka."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-001035","json":"https://secwatch.observer/filing/0001640334-23-001035.json","markdown":"https://secwatch.observer/filing/0001640334-23-001035.md","text":"https://secwatch.observer/filing/0001640334-23-001035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001035/0001640334-23-001035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001035/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:48:02.575545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64b554836a","claim":"Chris Bunka changed role as Principal Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"The Company’s Chief Executive Officer, Chris Bunka, will assume the role of principal financial officer at this time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001035/0001640334-23-001035-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"dbdf7f9bc6","claim":"Gregory Downey departed as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"Effective June 6, 2023, Mr. Gregory Downey was dismissed as the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001035/0001640334-23-001035-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"dismissed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}